Register
Login:
Share:
Email Facebook Twitter

Add Immupharma to quick picks

Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 42.50Bid: 42.00Ask: 43.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.00Spread as %: 2.38%Open: 42.50High: 42.50Low: 42.50Yesterday’s Close: 42.50

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Pharmaceuticals & Biotechnology sector




Intraday Immupharma Share Chart




Share Price SpacerPrice
42.50

Share Price SpacerBid
42.00

Share Price SpacerAsk
43.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
12,773

Share Price SpacerOpen
42.50

Share Price SpacerHigh
42.50

Share Price SpacerLow
42.50

Share Price SpacerClose
42.50

Share Price SpacerCurrency
GBX

3 Month Immupharma Share Graph




Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 82.28m £34.97m 5,000

52 Week High 77.75 52 Week High Date 25-SEP-2013
52 Week Low 41.50 52 Week Low Date 9-JUN-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
5 7,173 5,600 -9.403 -4.52 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

19-Sep-14
15:37:55
42.70
3,000
Buy* 
42.00
43.00
1,281
Trade Type:
Ordinary

19-Sep-14
10:17:25
42.70
600
Buy* 
42.00
43.00
256.20
Trade Type:
Ordinary

18-Sep-14
16:26:32
41.50
360
Sell* 
42.00
43.00
149.40
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
23-Jan-12Buy
Trade Notifier Information for Immupharma
Franco Di Muzio held the position of Non-Executive Director at Immupharma at the time of this trade.
 Franco Di Muzio
81GBX60,9500
View more Immupharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 09:19
TurnaShilling
Olderandwiser. Thu21-45
42.50
No Opinion

I endorse your post . Folk seem unable to see the wood from the trees , Invested for years &still at the start line . Pump &dump Brigade are the only folk showing a profit in this s.p. Clinging - on ,for the pot of gold ! Trouble is ,the rainbow is Aways miles away ,never overhead.
Thu 21:58
beaverburger
Interims
42.50
No Opinion

are due by the end of the month (I think) so we should have a reasonable idea of where we are. It is a slow and painful process watching the tumbleweed drift by but I bought in for the long term knowing that this might fester for some time. Hopefully it will pop soonish but I'm not holding my breath. If it drops to 30-35p then it becomes attractive again for me. Everyone has their own risk criteria and that needs to be respected.
Thu 21:55
sicilian_kan
O&W
42.50
No Opinion

Yes, it hasn't been ideal. But now is the time to be positive. News is coming. As for pivotal, you know as well as I do that all pivotal means is that it is a trial eligible to count towards FDA approval. Salaries are perfectly reasonable for what they do. Best thing for IMM is to get the Phase III started, and that is ready at the push of a button, with the deal to be announced soon.
Thu 21:45
Olderandwiser
RE: ....
42.50
No Opinion

What a depressing stock this has turned out to be. Isn't it at least a year now since our esteemed friends on Wall Street were hired to do a corporate deal for imm? Isn't it a year now since imm was granted an amended SPA by the FDA? Isn't it at least a year since imm appointed a group of key worldwide opinion makers to support Lupuzor's "pivotal Phase III programme"? Must be a pretty stable pivot, to last this long! And whatever happened to Wantonheart's iII buying that was supposed to kickstart the sp aover a month ago? Excuse my thinly veiled frustration but I'm tired of making excuses for this bod and their large personal shareholdings giving them heavy incentives to perform. No, it's the lure of high annual salaries unchallenged by a spread-out shareholder base that keeps them comfortable in this game, my friends, as well as the professional prestige of seeming to be at the cutting edge of new a Lupus therapy. How much longer will this be cutting edge, rather than a blunt breadnife? I give it another four years to milk, by which time the Darwin facility will have expired.
Thu 20:55
khameeleon
....
42.50
No Opinion

Not been here for a while, so good to see some posts and information, even if there is some contention. Given the complete lack of interest in the sp or the pi community displayed by the bod in recent times, it is almost impossible to find a credible motive for the recent article.... Both positive and negative posts here, personally I'm sitting on a small but uncomfortable paper loss and will hold to see what happens. Good luck to all whichever way you choose......this share has been frustrating to hold for sure
Thu 20:13
Wigwammer
Hh
42.50
No Opinion

All qns answered in previous posts, either here or advfn. Take it elsewhere.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.